BACKGROUND: Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib and IFN-α in patients with BRAFV600E melanoma may provide therapeutic benefits; MEK inhibition may prevent the reactivation of the MAPK pathway induced by BRAF inhibitor resistance. PATIENTS AND METHODS: In a phase I study, adult patients with advanced BRAFV600-mutated melanoma were treated with vemurafenib + PEG-IFN-α-2b or vemurafenib + cobimetinib + PEG-IFN-α-2b, to assess the safety of the combination and the upregulation of IFN-α/β receptor-1 (IFNAR1). RESULTS: Eight patients were treated; 59 adverse events with four serious ones (three related to study treatments) were reported. Patients with a pre-treatment IFNAR1 expression on ≤ 35% melanoma cells had a median progression-free survival of 12.0 months (range: 5.6-18.4 months) and a median overall survival of 31.0 months (range: 19.8-42.2 months), while patients with a pre-treatment IFNAR1 expression on > 35% of melanoma cells had a median progression-free survival of 4.0 months (range: 0-8.8; p = 0.03), and a median overall survival of 5 months (p = 0.02). Following treatment, responders had higher levels of growth-suppressor genes, including GAS1 and DUSP1, and genes involved in a metabolically robust immune response, including FAP. CONCLUSION: Our study supports the overall safety of the vemurafenib + PEG-IFN-α-2b + cobimetinib combination. IFNAR1 expression levels correlated with response to treatment, including survival. Vemurafenib + PEG-IFN-α-2b + cobimetinib would have difficulty finding a niche in the current treatment scenario for advanced melanoma, but we speculate that our findings may contribute to identify subjects particularly responsive to treatment. TRIAL REGISTRATION: The study was registered at clinicaltrials.gov (NCT01959633). Registered 10 October 2013, https://clinicaltrials.gov/ct2/show/NCT01959633.
BACKGROUND: Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib and IFN-α in patients with BRAFV600E melanoma may provide therapeutic benefits; MEK inhibition may prevent the reactivation of the MAPK pathway induced by BRAF inhibitor resistance. PATIENTS AND METHODS: In a phase I study, adult patients with advanced BRAFV600-mutated melanoma were treated with vemurafenib + PEG-IFN-α-2b or vemurafenib + cobimetinib + PEG-IFN-α-2b, to assess the safety of the combination and the upregulation of IFN-α/β receptor-1 (IFNAR1). RESULTS: Eight patients were treated; 59 adverse events with four serious ones (three related to study treatments) were reported. Patients with a pre-treatment IFNAR1 expression on ≤ 35% melanoma cells had a median progression-free survival of 12.0 months (range: 5.6-18.4 months) and a median overall survival of 31.0 months (range: 19.8-42.2 months), while patients with a pre-treatment IFNAR1 expression on > 35% of melanoma cells had a median progression-free survival of 4.0 months (range: 0-8.8; p = 0.03), and a median overall survival of 5 months (p = 0.02). Following treatment, responders had higher levels of growth-suppressor genes, including GAS1 and DUSP1, and genes involved in a metabolically robust immune response, including FAP. CONCLUSION: Our study supports the overall safety of the vemurafenib + PEG-IFN-α-2b + cobimetinib combination. IFNAR1 expression levels correlated with response to treatment, including survival. Vemurafenib + PEG-IFN-α-2b + cobimetinib would have difficulty finding a niche in the current treatment scenario for advanced melanoma, but we speculate that our findings may contribute to identify subjects particularly responsive to treatment. TRIAL REGISTRATION: The study was registered at clinicaltrials.gov (NCT01959633). Registered 10 October 2013, https://clinicaltrials.gov/ct2/show/NCT01959633.
Authors: Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais Journal: Cell Date: 2004-03-19 Impact factor: 41.582
Authors: Cynthia Cohen; Angel Zavala-Pompa; Judy H Sequeira; Mamoru Shoji; Deborah G Sexton; George Cotsonis; Francesca Cerimele; Baskaran Govindarajan; Nada Macaron; Jack L Arbiser Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: Anna Sophie Berghoff; Gerda Ricken; Georg Widhalm; Orsolya Rajky; Karin Dieckmann; Peter Birner; Rupert Bartsch; Christoph Höller; Matthias Preusser Journal: Histopathology Date: 2014-11-10 Impact factor: 5.087
Authors: Yibing Yan; Matthew J Wongchenko; Caroline Robert; James Larkin; Paolo A Ascierto; Brigitte Dréno; Michele Maio; Claus Garbe; Paul B Chapman; Jeffrey A Sosman; Zhen Shi; Hartmut Koeppen; Jessie J Hsu; Ilsung Chang; Ivor Caro; Isabelle Rooney; Grant A McArthur; Antoni Ribas Journal: Clin Cancer Res Date: 2019-03-01 Impact factor: 12.531
Authors: J Liu; K G Suresh Kumar; D Yu; S A Molton; M McMahon; M Herlyn; A Thomas-Tikhonenko; S Y Fuchs Journal: Oncogene Date: 2006-09-25 Impact factor: 9.867
Authors: O R Colamonici; B Porterfield; P Domanski; R K Handa; S Flex; C E Samuel; R Pine; M O Diaz Journal: J Biol Chem Date: 1994-11-04 Impact factor: 5.157
Authors: Francesco Sabbatino; Yangyang Wang; Giosuè Scognamiglio; Elvira Favoino; Steven A Feldman; Vincenzo Villani; Keith T Flaherty; Sjoerd Nota; Diana Giannarelli; Ester Simeone; Anna M Anniciello; Giuseppe Palmieri; Stefano Pepe; Gerardo Botti; Paolo A Ascierto; Cristina R Ferrone; Soldano Ferrone Journal: J Natl Cancer Inst Date: 2016-02-05 Impact factor: 11.816
Authors: Oluwaseyi T Shofolawe-Bakare; Larry D Stokes; Mehjabeen Hossain; Adam E Smith; Thomas A Werfel Journal: Biomater Sci Date: 2020-09-02 Impact factor: 6.843